From Real Estate Reinvention to Biotech Breakouts- These Are the Stocks to Watch into the Close

September 30, 2025

DENVER, Colo., Sep 30, 2025 (247marketnews.com)- As Wall Street sprints into the quarter’s final hour of trading, today’s tape is being driven by a potent mix of biotech breakthroughs, infrastructure reinvention, and bold bets on AI and digital assets. Here are the Power Hour Picks you need to keep on your radar into the close.

Venu Holdings (NYSE:VENU) is stealing the show after ThinkEquity reaffirmed its Buy rating and raised its price target to $18, citing the company as a “blueprint for a new asset class in experiential real estate.” VENU’s model blends hospitality, ticketing, and community-backed financing, offering more than just live shows, it’s a vertically integrated entertainment campus business.

ThinkEquity’s deep dive highlighted a capital-light, high-margin strategy with projected 2026 revenue of $270.9M and net income of $81.7M. Operational sites in Colorado Springs and Gainesville, with others underway in Texas and Oklahoma, position VENU as a real estate disruptor. The firm sees VENU not as a REIT or venue operator, but as “infrastructure for culture.”

Wolfspeed (NYSE:WOLF) is officially back. After emerging from Chapter 11, the silicon carbide leader is leaner and meaner, cutting its debt load by 70% and slashing cash interest by 60%. CEO Robert Feurle says WOLF is now “financially stable and positioned for an era of growth.”

The company will self-fund expansion of its 200mm vertically integrated fab, targeting the AI, EV, and energy sectors—key verticals for silicon carbide adoption. With a de-risked balance sheet and a strong product pipeline, WOLF is regaining institutional attention and could become a turnaround tech play heading into Q4.

AnaptysBio (NASDAQ:ANAB) plans to separate its biopharma development operations from its royalty and milestone revenue streams, forming two independent, publicly traded companies by year-end 2026. The move, approved by the Board of Directors, is designed to sharpen operational focus and unlock value across its immunology pipeline and royalty portfolio.

The proposed separation would create:

“Royalty Management Co” – Focused on managing and protecting the company’s existing and future royalty and milestone streams from partnerships, including Jemperli (with GSK) and imsidolimab (with Vanda Pharmaceuticals).

“Biopharma Co” – A development-focused company advancing AnaptysBio’s pipeline of next-generation immunology therapeutics, including rosnilimab, ANB033, and ANB101, targeting autoimmune and inflammatory diseases.

United Natural Foods, Inc. (NYSE:UNFI) reported its financial results for the fourth quarter and full fiscal year ended August 2, 2025, showing notable improvements in free cash flow and debt reduction, even as profitability remains under pressure.

Q4 Fiscal 2025 Highlights (vs. Q4 Fiscal 2024):

  • Net sales rose to $7.7 billion, up 1.6% on a comparable 13-week basis
  • Net loss of $(87) million, or $(1.43) per diluted share
  • Adjusted EBITDA came in at $116 million
  • Adjusted EPS was $(0.11)
  • Operating cash flow of $160 million and free cash flow of $86 million

Despite posting a net loss, UNFI’s Q4 results were in line with or ahead of most guidance midpoints, with net sales and free cash flow significantly outperforming the company’s original expectations.

Full-Year Fiscal 2025 Key Metrics:

  • Free cash flow improved by $331 million year-over-year
  • Net debt declined to $1.83 billion, the lowest level since 2018
  • Net leverage dropped by 0.7x, ending the year at 3.3x
  • Operational improvements were driven by the “lean daily management” program, now deployed across 28 distribution centers, delivering benefits in safety, quality, delivery, and cost efficiency

Outlook for Fiscal 2026:

UNFI is entering fiscal 2026 with positive momentum, setting guidance that reflects continued execution on strategic priorities. The company expects:

  • Adjusted EBITDA to grow approximately 20% year-over-year
  • A compound annual growth rate (CAGR) of nearly 15% since FY24, on a comparable basis

Management’s confidence in future performance is grounded in structural cost improvements, disciplined capital allocation, and ongoing operational initiatives aimed at strengthening the customer and supplier experience. As the largest publicly traded wholesale distributor of health and specialty food products in North America, UNFI’s focus on efficiency, debt reduction, and free cash flow generation positions it well amid macro uncertainty and margin pressures.

Vor Biopharma (NASDAQ:VOR) is following through today, after yesterday’s announcement that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren’s disease, which will be presented as a late-breaking poster presentation at ACR Convergence 2025, October 24-29, 2025, at McCormick Place in Chicago, Illinois.

Bakkt (NASDAQ:BKKT) is still ripping higher, which started after it redeemed its $150 million convertible debenture and nabbing a 30% stake in Japan’s MarushoHotta for blockchain payments expansion. Amid a $2 trillion crypto market rebound, BKKT’s debt wipeout, slashing long-term obligations to zero, bolsters its API solutions for 401(k) crypto pilots (per recent Trump EO). “We’re transforming into a blockchain-native payments leader,” management stated, with shares up 300% from August lows as Q3 volumes hit $1.2 billion.

CoreWeave (NASDAQ:CRWV) filed an 8-K disclosing a major infrastructure agreement with Meta Platforms, marking one of the company’s most significant commercial wins to date. The agreement outlines an initial commitment of up to $14.2 billion in spending through December 14, 2031, with the option to materially expand beyond that.

This deal highlights CoreWeave’s growing role as a key player in high-performance cloud infrastructure, particularly as hyperscalers like Meta seek specialized compute capacity to power AI workloads, LLMs, and immersive digital experiences.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

For the full 24/7 Market News VENU report and in-depth insights, visit: Read 24/7 Market News VENU Report/

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

24/7 MARKET NEWS, INC (247) Disclaimer and Disclosure
PAID EDITORIAL DISCLOSURE: 247MarketNews.com has been compensated $2,500 per week by MicroCap Strategies for ongoing press and editorial coverage of VENU. This is a paid editorial communication intended for informational purposes only. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. This press release may include technical analysis for informational purposes only and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, ANAB, WOLF, UNFI, BKKT, CRWV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.